Publication | Closed Access

Intracoronary followed by intravenous administration of the short-acting β-blocker landiolol prevents myocardial injury in the face of elective percutaneous coronary intervention

Percutaneous Coronary InterventionCardiac AnaesthesiaIntravenous AdministrationCardiovascular DiseaseMyocardial InfarctionPharmacologyCardiovascular PharmacologyShort-acting β-Blocker LandiololPublic HealthMedicineCardiologyMyocardial InjuryAcute Myocardial InfarctionCardiovascular Imaging